134 related articles for article (PubMed ID: 23944905)
1. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.
Rossi GC; Blini M; Scudeller L; Ricciardelli G; Depolo L; Amisano A; Bossolesi L; Pasinetti GM; Bianchi PE
J Ocul Pharmacol Ther; 2013 Nov; 29(9):821-5. PubMed ID: 23944905
[TBL] [Abstract][Full Text] [Related]
2. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
3. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
4. An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy.
Rossi GCM; Scudeller L; Lumini C; Mirabile AV; Picasso E; Bettio F; Pasinetti GM; Bianchi PE
Sci Rep; 2019 Mar; 9(1):4282. PubMed ID: 30862874
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
Holló G; Hommer A; Antón López A; Ropo A
J Ocul Pharmacol Ther; 2014 Aug; 30(6):468-75. PubMed ID: 24738883
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
[TBL] [Abstract][Full Text] [Related]
7. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
Oddone F; Tanga L; Kóthy P; Holló G;
Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
[TBL] [Abstract][Full Text] [Related]
10. Spanish multicenter tafluprost tolerability study.
Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM
Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693
[TBL] [Abstract][Full Text] [Related]
11. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE
Expert Opin Drug Saf; 2012 Jul; 11(4):519-25. PubMed ID: 22690824
[TBL] [Abstract][Full Text] [Related]
13. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study.
Baratz KH; Nau CB; Winter EJ; McLaren JW; Hodge DO; Herman DC; Bourne WM
Cornea; 2006 Oct; 25(9):1046-52. PubMed ID: 17133051
[TBL] [Abstract][Full Text] [Related]
14. Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
Chabi A; Baranak C; Lupinacci R; Herring WJ
Int J Clin Pract; 2016 Jul; 70(7):577-86. PubMed ID: 27292765
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A
Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Uusitalo H; Pillunat LE; Ropo A;
Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
[TBL] [Abstract][Full Text] [Related]
17. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Erb C; Lanzl I; Seidova SF; Kimmich F
Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
[TBL] [Abstract][Full Text] [Related]
18. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.
Fogagnolo P; Dipinto A; Vanzulli E; Maggiolo E; De Cilla' S; Autelitano A; Rossetti L
Adv Ther; 2015 Apr; 32(4):356-69. PubMed ID: 25893514
[TBL] [Abstract][Full Text] [Related]
19. Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
Kuwayama Y; Hashimoto M; Kakegawa R; Nomura A; Shimada F
Adv Ther; 2017 Jun; 34(6):1411-1425. PubMed ID: 28502035
[TBL] [Abstract][Full Text] [Related]
20. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study.
Mastropasqua L; Agnifili L; Fasanella V; Curcio C; Ciabattoni C; Mastropasqua R; Toto L; Ciancaglini M
Acta Ophthalmol; 2013 Aug; 91(5):e397-405. PubMed ID: 23601909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
